Clinicopathological Outcomes and Prognosis of Elderly Patients (≥ 65 Years) with Gastric Gastrointestinal Stromal Tumors (GISTs) Undergoing Curative-Intent Resection: a Multicenter Data Review
- 129 Downloads
The most common site of gastrointestinal stromal tumors (GISTs) is the stomach, and gastric GISTs (gGISTs) occur most often in elderly patients. However, the clinicopathological features, treatment patterns, and prognosis of elderly patients with gGISTs remain unclear.
We retrospectively collected clinicopathological and prognostic data for patients with primary gGISTs who underwent curative-intent resection at 10 medical centers in China from 1998 to 2015.
Over the 18 years, 10 medical centers treated 1846 patients with primary gGISTs by curative-intent resection. The median age was 59 (range 18–91) years. The patients were classified into two groups according to age, namely an elderly group (≥ 65 years of age) and a nonelderly group (< 65 years of age). The elderly group had more comorbidities (40.7% vs 23.5%, p = 0.011), a higher rate of postoperative complications (14.4% vs 8.7%, p = 0.031), and a lower proportion of intermediate/high-risk patients who received adjuvant therapy (30.0% vs 66.8%, p = 0.001) than did the nonelderly group. Regarding pathological outcomes, a significant difference in tumor necrosis was observed between the two groups (p = 0.002), and more cases of tumor necrosis occurred in the elderly group than in the nonelderly group. Regarding postoperative recovery outcomes, no significant difference was observed between the two groups. Univariate analysis showed that age, postoperative complications, adjuvant therapy, tumor size, mitotic count, modified National Institutes of Health (NIH) risk category, and tumor necrosis were factors that affected disease-free survival (DFS). Multivariate analysis showed that modified NIH risk category was the only independent factor affecting DFS. The 5-year DFS rates in the nonelderly and elderly groups were 88.1% and 81.4%, respectively (p = 0.034), and the 5-year overall survival (OS) rates were 90.4% and 85.5% (p = 0.038), respectively.
Currently, the treatment patterns for elderly patients with gGISTs remain the same as those for young patients with gGISTs. Elderly gGIST patients had more comorbidities and postoperative complications than did nonelderly gGIST patients, and fewer elderly gGIST patients received postoperative adjuvant therapy. Elderly gGIST patients also had a higher rate of tumor necrosis and worse DFS and OS than did young gGIST patients. Further exploration into the diagnosis and treatment patterns of elderly patients is therefore essential.
KeywordsClinicopathological outcomes Prognosis Gastric GIST Elderly patients
Dr. Zifeng Yang would like to acknowledge the support and guidance received from his postgraduate mentor, Prof. Li Yong, in the past 4 years. In addition, he would also like to thank Lianye Zhang for the constant patience, care, and love.
All authors listed above have made substantial contributions to the conception and design of this study, have revised its intellectual content, and have approved the final submitted version of the manuscript.
This study was supported by the Natural Science Foundation of Guangdong Province (2016A030310328) and Medical Scientific Research Foundation of Guangdong Province, People’s Republic of China (A2016228).
Compliance with Ethical Standards
We received ethics approval for this case series from 10 medical centers in China (Guangdong General Hospital; Guangdong Academy of Medical Science, Guangzhou, People’s Republic of China; Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, People’s Republic of China; Southern Medical University Nanfang Hospital, Guangzhou, People’s Republic of China; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, People’s Republic of China; Fujian Medical University Union Hospital, Fuzhou, People’s Republic of China; Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; West China Hospital, Sichuan University, Chengdu, People’s Republic of China; Peking University Cancer Hospital and Institute, Beijing, People’s Republic of China; Liaoning Cancer Hospital and Institute, Shenyang, People’s Republic of China; People’s Liberation Army Cancer Center; 81st Hospital of PLA, Nanjing, People’s Republic of China).
Informed consent was obtained from all individual participants included in the study.
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 1.Ma GL, Murphy JD, Martinez ME, Sicklick JK (2015) Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 24:298–302CrossRefGoogle Scholar
- 5.Farag S, van Coevorden F, Sneekes E, Grunhagen DJ, Reyners AKL, Boonstra PA, van der Graaf WT, Gelderlyblom HJ, Steeghs N (2017) Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity—A retrospective multicentre study in a large cohort of GIST patients. European journal of cancer 86:318–325CrossRefGoogle Scholar
- 6.von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU, 3rd, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM, 3rd, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Tap WD, Wayne JD, Bergman MA, Scavone J (2016) Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 14:758–786CrossRefGoogle Scholar
- 10.Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology Group Intergroup Adjuvant GST (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097–1104CrossRefGoogle Scholar
- 11.Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegard T, Reichardt P (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. Jama 307:1265–1272CrossRefGoogle Scholar
- 12.Milone M, Elmore U, Vignali A, Mellano A, Gennarelli N, Manigrasso M, Milone F, De Palma GD, Muratore A, Rosati R (2017) Pulmonary Complications after Surgery for Rectal Cancer in Elderly Patients: Evaluation of Laparoscopic versus Open Approach from a Multicenter Study on 477 Consecutive Cases. Gastroenterology research and practice 2017:5893890CrossRefGoogle Scholar
- 13.Yamano T, Yamauchi S, Kimura K, Babaya A, Hamanaka M, Kobayashi M, Fukumoto M, Tsukamoto K, Noda M, Tomita N, Sugihara K, Japanese Study Group for Postoperative Follow-up of Colorectal C (2017) Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study. European journal of cancer 81:90–101CrossRefGoogle Scholar
- 17.Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ (2014) Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients—a chart extract-based approach. Journal of gastrointestinal cancer 45:431–440CrossRefGoogle Scholar
- 19.Liu X, Qiu H, Zhang P, Feng X, Chen T, Li Y, Tao K, Li G, Sun X, Zhou Z, China Gastrointestinal Stromal Tumor Study G (2017) Prognostic role of tumor necrosis in patients undergoing curative intent resection for gastric gastrointestinal stromal tumor: a multicenter analysis of 740 cases in China. Cancer medicineGoogle Scholar
- 20.Hiraoka N, Ino Y, Sekine S, Tsuda H, Shimada K, Kosuge T, Zavada J, Yoshida M, Yamada K, Koyama T, Kanai Y (2010) Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. British journal of cancer 103:1057–1065CrossRefGoogle Scholar
- 21.Cho MY, Sohn JH, Kim JM, Kim KM, Park YS, Kim WH, Jung JS, Jung ES, Jin SY, Kang DY, Park JB, Park HS, Choi YD, Sung SH, Kim YB, Kim H, Bae YK, Kang M, Chang HJ, Chae YS, Lee HE, Park DY, Lee YS, Kang YK, Kim HK, Chang HK, Hong SW, Choi YH, Shin O, Gu M, Kim YW, Kim GI, Chang SJ (2010) Current trends in the epidemiological and pathological characteristics of gastrointestinal stromal tumors in Korea, 2003-2004. Journal of Korean medical science 25:853–862CrossRefGoogle Scholar
- 23.Yin Z, Gao J, Liu W, Huang C, Shuai X, Wang G, Tao K, Zhang P (2017) Clinicopathological and Prognostic Analysis of Primary Gastrointestinal Stromal Tumor Presenting with Gastrointestinal Bleeding: a 10-Year Retrospective Study. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 21:792–800CrossRefGoogle Scholar